Literature DB >> 16320324

Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice.

Alexandra P Treschow1, Ingrid Teige, Kutty S Nandakumar, Rikard Holmdahl, Shohreh Issazadeh-Navikas.   

Abstract

OBJECTIVE: Clinical trials using interferon-beta (IFNbeta) in the treatment of rheumatoid arthritis have shown conflicting results. We undertook this study to understand the mechanisms of IFNbeta in arthritis at a physiologic level.
METHODS: Collagen-induced arthritis (CIA) was induced in IFNbeta-deficient and control mice. The role of IFNbeta was investigated in both the priming and effector phases of the disease. The effect of IFNbeta deficiency on synovial cells, macrophages, and fibroblasts from preimmunized mice was analyzed by flow cytometry, immunohistochemistry, and enzyme-linked immunosorbent assay. Differences in osteoclast maturation were determined in situ by histology of arthritic and naive paws and by in vitro maturation studies of naive bone marrow cells. The importance of IFNbeta-producing fibroblasts was determined by transferring fibroblasts into mice at the time of CIA immunization.
RESULTS: Mice lacking IFNbeta had a prolonged disease with a higher incidence compared with control mice. IFNbeta deficiency was found to influence the effector phase, but not the priming phase, of arthritis. Compared with control mice, IFNbeta-deficient mice had greater infiltration of CD11b+ cells and greater production of tumor necrosis factor alpha in vivo, and their macrophages and fibroblasts were both more activated in vitro. Moreover, IFNbeta-deficient mice generated a greater number of osteoclasts in vitro, and mice immunized to induce arthritis, but not naive mice, had a greater number of osteoclasts in vivo compared with control mice. Importantly, IFNbeta-competent fibroblasts were able to ameliorate arthritis in IFNbeta-deficient recipients.
CONCLUSION: Our data indicate that IFNbeta is involved in regulating the activation state of osteoclasts and stromal cells, including macrophages and fibroblasts, but that it has little effect on T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16320324     DOI: 10.1002/art.21496

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  20 in total

1.  Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.

Authors:  Clio P Mavragani; Dan T La; William Stohl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2010-02

2.  Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.

Authors:  T C T M van der Pouw Kraan; C A Wijbrandts; L G M van Baarsen; A E Voskuyl; F Rustenburg; J M Baggen; S M Ibrahim; M Fero; B A C Dijkmans; P P Tak; C L Verweij
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

3.  Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis.

Authors:  Maripat Corr; David L Boyle; Lisa M Ronacher; Brian R Lew; Lisa G van Baarsen; Paul P Tak; Gary S Firestein
Journal:  Ann Rheum Dis       Date:  2011-01-07       Impact factor: 19.103

Review 4.  Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance.

Authors:  Tineke Cantaert; Dominique Baeten; Paul P Tak; Lisa G M van Baarsen
Journal:  Arthritis Res Ther       Date:  2010-10-28       Impact factor: 5.156

Review 5.  Type I interferon in organ-targeted autoimmune and inflammatory diseases.

Authors:  Mary K Crow
Journal:  Arthritis Res Ther       Date:  2010-08-25       Impact factor: 5.156

6.  Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta.

Authors:  M Corr; D L Boyle; L Ronacher; N Flores; G S Firestein
Journal:  Ann Rheum Dis       Date:  2008-07-24       Impact factor: 19.103

Review 7.  Molecular mechanisms of the anti-inflammatory functions of interferons.

Authors:  Pavel Kovarik; Ines Sauer; Barbara Schaljo
Journal:  Immunobiology       Date:  2007-11-08       Impact factor: 3.144

8.  Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats.

Authors:  J Adriaansen; F J Fallaux; C J de Cortie; M J Vervoordeldonk; P P Tak
Journal:  J Gen Virol       Date:  2007-06       Impact factor: 3.891

9.  Pro-Inflammatory Signaling by IL-10 and IL-22: Bad Habit Stirred Up by Interferons?

Authors:  Heiko Mühl
Journal:  Front Immunol       Date:  2013-02-04       Impact factor: 7.561

10.  Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis.

Authors:  Brian J Schmidt; Fergal P Casey; Thomas Paterson; Jason R Chan
Journal:  BMC Bioinformatics       Date:  2013-07-10       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.